These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
316 related articles for article (PubMed ID: 20961400)
1. Histone deacetylases and mood disorders: epigenetic programming in gene-environment interactions. Machado-Vieira R; Ibrahim L; Zarate CA CNS Neurosci Ther; 2011 Dec; 17(6):699-704. PubMed ID: 20961400 [TBL] [Abstract][Full Text] [Related]
2. Epigenetic evidence of an Ac/Dc axis by VPA and SAHA. Lunke S; Maxwell S; Khurana I; K N H; Okabe J; Al-Hasani K; El-Osta A Clin Epigenetics; 2021 Mar; 13(1):58. PubMed ID: 33743782 [TBL] [Abstract][Full Text] [Related]
3. Altered gene expression of histone deacetylases in mood disorder patients. Hobara T; Uchida S; Otsuki K; Matsubara T; Funato H; Matsuo K; Suetsugi M; Watanabe Y J Psychiatr Res; 2010 Apr; 44(5):263-70. PubMed ID: 19767015 [TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors as Cognitive Enhancers and Modifiers of Mood and Behavior. Pal D; Sahu P; Mishra AK; Hagelgans A; Sukocheva O Curr Drug Targets; 2023; 24(9):728-750. PubMed ID: 36475351 [TBL] [Abstract][Full Text] [Related]
5. [Epigenetic mechanisms and alcohol use disorders: a potential therapeutic target]. Legastelois R; Jeanblanc J; Vilpoux C; Bourguet E; Naassila M Biol Aujourdhui; 2017; 211(1):83-91. PubMed ID: 28682229 [TBL] [Abstract][Full Text] [Related]
7. Histone deacetylases (HDACs) as therapeutic target for depressive disorders. Misztak P; Pańczyszyn-Trzewik P; Sowa-Kućma M Pharmacol Rep; 2018 Apr; 70(2):398-408. PubMed ID: 29456074 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic modulation: Research progress on histone acetylation levels in major depressive disorders. Meng Y; Du J; Liu N; Qiang Y; Xiao L; Lan X; Ma L; Yang J; Yu J; Lu G J Drug Target; 2023 Feb; 31(2):142-151. PubMed ID: 36112185 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. Phiel CJ; Zhang F; Huang EY; Guenther MG; Lazar MA; Klein PS J Biol Chem; 2001 Sep; 276(39):36734-41. PubMed ID: 11473107 [TBL] [Abstract][Full Text] [Related]
10. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis. Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408 [TBL] [Abstract][Full Text] [Related]
11. Targeting AML1/ETO-histone deacetylase repressor complex: a novel mechanism for valproic acid-mediated gene expression and cellular differentiation in AML1/ETO-positive acute myeloid leukemia cells. Liu S; Klisovic RB; Vukosavljevic T; Yu J; Paschka P; Huynh L; Pang J; Neviani P; Liu Z; Blum W; Chan KK; Perrotti D; Marcucci G J Pharmacol Exp Ther; 2007 Jun; 321(3):953-60. PubMed ID: 17389244 [TBL] [Abstract][Full Text] [Related]
12. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Milutinovic S; D'Alessio AC; Detich N; Szyf M Carcinogenesis; 2007 Mar; 28(3):560-71. PubMed ID: 17012225 [TBL] [Abstract][Full Text] [Related]
13. HDAC inhibition through valproic acid modulates the methylation profiles in human embryonic kidney cells. Ganai SA; Kalladi SM; Mahadevan V J Biomol Struct Dyn; 2015; 33(6):1185-97. PubMed ID: 25012937 [TBL] [Abstract][Full Text] [Related]
14. Vulnerability to opiate intake in maternally deprived rats: implication of MeCP2 and of histone acetylation. Tesone-Coelho C; Morel LJ; Bhatt J; Estevez L; Naudon L; Giros B; Zwiller J; Daugé V Addict Biol; 2015 Jan; 20(1):120-31. PubMed ID: 23980619 [TBL] [Abstract][Full Text] [Related]
15. The mood stabilizer valproate activates human FGF1 gene promoter through inhibiting HDAC and GSK-3 activities. Kao CY; Hsu YC; Liu JW; Lee DC; Chung YF; Chiu IM J Neurochem; 2013 Jul; 126(1):4-18. PubMed ID: 23647222 [TBL] [Abstract][Full Text] [Related]
17. The role dietary of bioactive compounds on the regulation of histone acetylases and deacetylases: a review. Vahid F; Zand H; Nosrat-Mirshekarlou E; Najafi R; Hekmatdoost A Gene; 2015 May; 562(1):8-15. PubMed ID: 25701602 [TBL] [Abstract][Full Text] [Related]
18. Deacetylation of chromatin and gene expression regulation: a new target for epigenetic therapy. Olzscha H; Sheikh S; La Thangue NB Crit Rev Oncog; 2015; 20(1-2):1-17. PubMed ID: 25746101 [TBL] [Abstract][Full Text] [Related]
19. Histone tail modifications and noncanonical functions of histones: perspectives in cancer epigenetics. Hadnagy A; Beaulieu R; Balicki D Mol Cancer Ther; 2008 Apr; 7(4):740-8. PubMed ID: 18413789 [TBL] [Abstract][Full Text] [Related]
20. Epigenetic therapy of cancer with histone deacetylase inhibitors. Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]